AusTrials - Sunshine
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rasalam, Roy
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Completed
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
01/25
NCT06389487: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Completed
3
1459
Europe, Canada, Japan, US, RoW
RSVPreF3 OA investigational vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
07/24
03/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rasalam, Roy
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Completed
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
01/25
NCT06389487: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Completed
3
1459
Europe, Canada, Japan, US, RoW
RSVPreF3 OA investigational vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
07/24
03/25

Download Options